Embattled genetic testing provider 23andMe said Tuesday that revenue declined from a year earlier, a day after the company announced a cost-cutting plan.
Related Posts
Asia-Pacific markets open lower as U.S. data stokes fears of sticky inflation and slower growth
Japanese markets are closed for a public holiday.
Nvidia to anchor CoreWeave IPO at $40 a share, source says
Wall Street was optimistic that President Trump term would be more favorable for technology stocks, but the sector has gotten off to a rough start […]
Goldman’s retail stock picks for Black Friday and the holidays
Goldman surveyed 1,000 U.S. consumers about holiday shopping plans and came away largely encouraged by an improving inflationary backdrop for shoppers.